Multiple sclerosis trials in North Macedonia

1 trial · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 2Taking people
  A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

  Where

  Shtip, Skopje

  Age

  18 years to 65 years

  People

  350 worldwide

  Run by

  TG Therapeutics, Inc.

  See details and how to joinNCT07503873 · EU 2025-523757-33-00